Tag: stageIII

Stage III breast cancer: Breast cancer with at least one of the following characteristics: (1) large tumor size (> 5 cm) and at least 1 positive axillary lymph node; (2) at least 4 positive lymph nodes or has spread to internal mammary or clavicular lymph nodes; (3) tumor has grown into the chest wall or skin.

News

09/28/11: Zoledronic acid might reduce recurrence in postmenopausal women

Studies

Ribociclib plus Endocrine Therapy in Early Breast Cancer Cite
Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2024; 390:1080-1091 10.1056/nejmoa2305488
Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study Cite
Parrish KM, Thomas SM, Cartwright SB, van den Bruele AB, Zasloff R, DiLalla GA, et al. Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2024; 10.1245/s10434-024-16026-w
Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer Cite
Leone J, Hassett MJ, Freedman RA, Tolaney SM, Graham N, Tayob N, et al. Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer. JAMA Oncology. American Medical Association (AMA); 2024; 10.1001/jamaoncol.2023.7194
Inhaled anesthesia associated with reduced mortality in patients with stage III breast cancer: A population-based study Cite
Kuo ET, Kuo C, Lin C. Inhaled anesthesia associated with reduced mortality in patients with stage III breast cancer: A population-based study. PLOS ONE. Public Library of Science (PLoS); 2024; 19:e0289519 10.1371/journal.pone.0289519
Effectiveness of Nigella sativa Addition against TNF-Alpha in Stage III and IV Breast Cancer Undergoing Doxorubicin and Cyclophosphamide Chemotherapy at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia Cite
Friyoga Syahril , Wirdah A, Nur Qodir , Irfanuddin , Irsan Saleh , Yenny Dian Andayani , et al. Effectiveness of Nigella sativa Addition against TNF-Alpha in Stage III and IV Breast Cancer Undergoing Doxorubicin and Cyclophosphamide Chemotherapy at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia. Bioscientia Medicina : Journal of Biomedicine and Translational Research. Hanif Medisiana Publisher; 2023; 8:4009-4014 10.37275/bsm.v8i2.924
Post Mastectomy Radiation Therapy Impact on Clinical Outcomes of Male Breast Cancer: A Meta-Analysis of Comparative Studies Cite
Haddad P, Zaheer U. Post Mastectomy Radiation Therapy Impact on Clinical Outcomes of Male Breast Cancer: A Meta-Analysis of Comparative Studies. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2023; 117:e176 10.1016/j.ijrobp.2023.06.1023
Abstract 743: Association between physical activity and lipid profile among breast cancer survivors Cite
Cho HJ, Kang M, Kim Z, Youn HJ, Cho J, Min JW, et al. Abstract 743: Association between physical activity and lipid profile among breast cancer survivors. Cancer Research. American Association for Cancer Research (AACR); 2023; 83:743-743 10.1158/1538-7445.am2023-743
Abstract PD6-10: PD6-10 The impact of post mastectomy radiation therapy on clinical outcomes of male breast cancer: A meta-analysis of comparative studies Cite
Haddad PA, Zaheer U. Abstract PD6-10: PD6-10 The impact of post mastectomy radiation therapy on clinical outcomes of male breast cancer: A meta-analysis of comparative studies. Cancer Research. American Association for Cancer Research (AACR); 2023; 83:PD6-10-PD6-10 10.1158/1538-7445.sabcs22-pd6-10
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer. Cite
Sparano JA, O’Neill A, Graham N, Northfelt DW, Dang CT, Wolff AC, et al. Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer.. npj Breast Cancer. Springer Science and Business Media LLC; 2022; 8 10.1038/s41523-021-00376-9
Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I–III unilateral breast cancer in the USA, 1998–2016 Cite
Yang Y, Pan L, Shao Z. Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I–III unilateral breast cancer in the USA, 1998–2016. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06397-z
Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women Cite
Cairat M, Al Rahmoun M, Gunter MJ, Heudel P, Severi G, Dossus L, et al. Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women. BMC Medicine. Springer Science and Business Media LLC; 2021; 19 10.1186/s12916-021-02004-6
Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry Cite
Yamada A, Kumamaru H, Shimizu C, Taira N, Nakayama K, Miyashita M, et al. Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry. European Journal of Cancer. Elsevier BV; 2021; 154:157-166 10.1016/j.ejca.2021.06.006
Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry Cite
Leone JP, Leone BA, Tayob N, Hassett MJ, Leone J, Freedman RA, et al. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06121-x
Five-year relative survival by stage of breast and colon cancers in Italy Cite
Mangone L, Mancuso P, Bisceglia I, Braghiroli B, Ferrari F, Vicentini M, et al. Five-year relative survival by stage of breast and colon cancers in Italy. Tumori Journal. SAGE Publications; 2020;:030089162096456 10.1177/0300891620964565
The role of adjuvant chemotherapy in stage I–III male breast cancer: a SEER-based analysis Cite
Li W, Gao H, Ji F, Zhu T, Cheng M, Yang M, et al. The role of adjuvant chemotherapy in stage I–III male breast cancer: a SEER-based analysis. Therapeutic Advances in Medical Oncology. SAGE Publications; 2020; 12:175883592095835 10.1177/1758835920958358
Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study Cite
Sant M, Meneghini E, Bastos J, Rossi PG, Guevara M, Innos K, et al. Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 183:439-450 10.1007/s10549-020-05761-9
Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial Cite
de Groot S, Lugtenberg RT, Cohen D, Welters MJP, Ehsan I, Vreeswijk MPG, et al. Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nature Communications. Springer Science and Business Media LLC; 2020; 11 10.1038/s41467-020-16138-3
Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients Cite
Schneider J, Lee HJ, Nam SJ, Lee SJ, Jung JH, Jung SH, et al. Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer. Korean Breast Cancer Society; 2020; 23:259 10.4048/jbc.2020.23.e34
Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC Cite
Iwase T, Harano K, Masuda H, Kida K, Hess KR, Wang Y, et al. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer. Springer Science and Business Media LLC; 2020; 20 10.1186/s12885-020-06940-z
Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation Cite
Keilty D, Nezafat Namini S, Swain M, Maganti M, Cil TD, McCready DR, et al. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2020; 108:676-685 10.1016/j.ijrobp.2020.04.044
Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database Cite
Fabiano V, Mandó P, Rizzo M, Ponce C, Coló F, Loza M, et al. Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database. JCO Global Oncology. American Society of Clinical Oncology (ASCO); 2020;:639-646 10.1200/jgo.19.00228
Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016 Cite
Thomas A, Rhoads A, Suhl J, Conway KM, Hundley WG, McNally LR, et al. Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016. Clinical Breast Cancer. Elsevier BV; 2020; 20:e410-e422 10.1016/j.clbc.2020.01.014
Outcomes of primary endocrine therapy in elderly women with stage I–III breast cancer: a SEER database analysis Cite
Yuan C, Xie Z, Bian J, Huo J, Daily K. Outcomes of primary endocrine therapy in elderly women with stage I–III breast cancer: a SEER database analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:819-827 10.1007/s10549-020-05591-9
The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women’s Health Initiative Cite
Yung R, Ray RM, Roth J, Johnson L, Warnick G, Anderson GL, et al. The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women’s Health Initiative. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:747-757 10.1007/s10549-020-05572-y
Outcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01) Cite
Stankowski-Drengler TJ, Schumacher JR, Hanlon B, Livingston-Rosanoff D, Van de Walle K, Greenberg CC, et al. Outcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01). Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 27:637-644 10.1245/s10434-019-07846-2
Systemic Inflammation After Radiation Predicts Locoregional Recurrence, Progression, and Mortality in Stage II-III Triple-Negative Breast Cancer Cite
Sherry AD, von Eyben R, Newman NB, Gutkin P, Mayer I, Horst K, et al. Systemic Inflammation After Radiation Predicts Locoregional Recurrence, Progression, and Mortality in Stage II-III Triple-Negative Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2020; 108:268-276 10.1016/j.ijrobp.2019.11.398
Role of Curcumin in reducing toxicity and adverse effects in locally advanced and metastatic breast cancer patients Cite
Goyal S, Beniwal SK, Kumar H, Kumar D, Das B. Role of Curcumin in reducing toxicity and adverse effects in locally advanced and metastatic breast cancer patients. Annals of Oncology. Elsevier BV; 2019; 30:vi126-vi127 10.1093/annonc/mdz343.041
Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice Cite
Saw S, Lim J, Lim SH, Wong M, Lim C, Yap YS. Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 177:197-206 10.1007/s10549-019-05290-0
Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990–2011 Cite
Malmgren J, Hurlbert M, Atwood M, Kaplan HG. Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990–2011. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 174:505-514 10.1007/s10549-018-05090-y
Receipt of Guideline-Concordant Care Among Older Women With Stage I–III Breast Cancer: A Population-Based Study Cite
LeMasters T, Madhavan SS, Sambamoorthi U, Hazard-Jenkins HW, Kelly KM, Long D. Receipt of Guideline-Concordant Care Among Older Women With Stage I–III Breast Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network. Harborside Press, LLC; 2018; 16:703-710 10.6004/jnccn.2018.7004
Development of CNS metastases and survival in patients with inflammatory breast cancer Cite
Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, et al. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. Wiley; 2018; 124:2299-2305 10.1002/cncr.31336
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer Cite
Fujii T, Kogawa T, Dong W, Sahin A, Moulder S, Litton J, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Annals of Oncology. Elsevier BV; 2017; 28:2420-2428 10.1093/annonc/mdx397
Patterns and predictors of first and subsequent recurrence in women with early breast cancer Cite
Geurts YM, Witteveen A, Bretveld R, Poortmans PM, Sonke GS, Strobbe LJA, et al. Patterns and predictors of first and subsequent recurrence in women with early breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 165:709-720 10.1007/s10549-017-4340-3
Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients Cite
Shiao J, Thomas KM, Rahimi AS, Rao R, Yan J, Xie X, et al. Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 161:463-471 10.1007/s10549-016-4081-8
Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence Cite
Brothers JM, Kidwell KM, Brown RKJ, Henry NL. Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:395-403 10.1007/s10549-016-3687-1
Abstract 855: History of oral contraceptive use in breast cancer patients and risk for early breast cancer events Cite
Huzell L, Persson M, Simonsson M, Markkula A, Ingvar C, Rose C, et al. Abstract 855: History of oral contraceptive use in breast cancer patients and risk for early breast cancer events. Epidemiology. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-855
The association between diabetes and breast cancer stage at diagnosis: a population-based study Cite
Lipscombe LL, Fischer HD, Austin PC, Fu L, Jaakkimainen RL, Ginsburg O, et al. The association between diabetes and breast cancer stage at diagnosis: a population-based study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 150:613-620 10.1007/s10549-015-3323-5
Inflammatory Breast Cancer Management in the National Comprehensive Cancer Network: The Disease, Recurrence Pattern, and Outcome Cite
Matro JM, Li T, Cristofanilli M, Hughes ME, Ottesen RA, Weeks JC, et al. Inflammatory Breast Cancer Management in the National Comprehensive Cancer Network: The Disease, Recurrence Pattern, and Outcome. Clinical Breast Cancer. Elsevier BV; 2015; 15:1-7 10.1016/j.clbc.2014.05.005
Survival of women with inflammatory breast cancer: a large population-based study Cite
Dawood S, Lei X, Dent R, Gupta S, Sirohi B, Cortes J, et al. Survival of women with inflammatory breast cancer: a large population-based study. Annals of Oncology. Elsevier BV; 2014; 25:1143-1151 10.1093/annonc/mdu121
Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer Cite
Gagliato DdM, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, et al. Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014; 32:735-744 10.1200/jco.2013.49.7693
Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands Cite
Janssen-Heijnen M, van Steenbergen L, Voogd A, Tjan-Heijnen V, Nijhuis P, Poortmans P, et al. Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands. Annals of Oncology. Elsevier BV; 2014; 25:64-68 10.1093/annonc/mdt424
Male Breast Cancer: 20-Year Survival Data for Post-Mastectomy Radiotherapy Cite
Eggemann H, Ignatov A, Stabenow R, von Minckwitz G, Röhl FW, Hass P, et al. Male Breast Cancer: 20-Year Survival Data for Post-Mastectomy Radiotherapy. Breast Care. S. Karger AG; 2013; 8:270-275 10.1159/000354122
Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: a cohort study Cite
Contiero P, Berrino F, Tagliabue G, Mastroianni A, Di Mauro MG, Fabiano S, et al. Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: a cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2013; 138:951-959 10.1007/s10549-013-2519-9
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse Cite
Jain S, Cohen J, Ward M, Kornhauser N, Chuang E, Cigler T, et al. Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Annals of Oncology. Elsevier BV; 2013; 24:1491-1498 10.1093/annonc/mds654
Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer Cite
Pedersen AC, Sørensen PD, Jacobsen EH, Madsen JS, Brandslund I. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Clinical Chemistry and Laboratory Medicine. Walter de Gruyter GmbH; 2013; 51 10.1515/cclm-2012-0488
Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China Cite
Zhang L, Hao C, Dong G, Tong Z. Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China. Breast Care. S. Karger AG; 2012; 7:13-17 10.1159/000336539
Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers. Cite
Ambros T, Sujoy V, Fernandez CG, Reis I, Wright JL, Jorda M, et al. Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:132-132 10.1200/jco.2011.29.27_suppl.132
Breast-Cancer Adjuvant Therapy with Zoledronic Acid Cite
Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-Cancer Adjuvant Therapy with Zoledronic Acid. New England Journal of Medicine. Massachusetts Medical Society; 2011; 365:1396-1405 10.1056/nejmoa1105195
Beta Blockers and Breast Cancer Mortality: A Population- Based Study Cite
Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta Blockers and Breast Cancer Mortality: A Population- Based Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:2635-2644 10.1200/jco.2010.33.5422
Impact of body mass index on clinical outcomes in triple-negative breast cancer Cite
Ademuyiwa FO, Groman A, O'Connor T, Ambrosone C, Watroba N, Edge SB. Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer. Wiley; 2011; 117:4132-4140 10.1002/cncr.26019
Higher population-based incidence rates of triple-negative breast cancer among young African-American women Cite
Amirikia KC, Mills P, Bush J, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young African-American women. Cancer. Wiley; 2011; 117:2747-2753 10.1002/cncr.25862
African ancestry and higher prevalence of triple-negative breast cancer Cite
Stark A, Kleer CG, Martin I, Awuah B, Nsiah-Asare A, Takyi V, et al. African ancestry and higher prevalence of triple-negative breast cancer. Cancer. Wiley; 2010; 116:4926-4932 10.1002/cncr.25276
Diabetes, obesity, and survival in a large cohort of early-stage breast cancer patients. Cite
Giordano SH, Jiralerspong S, Lopez A, Feng L, Kim ES, Gonzalez-Angulo AM, et al. Diabetes, obesity, and survival in a large cohort of early-stage breast cancer patients.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1503-1503 10.1200/jco.2010.28.15_suppl.1503
Male breast cancer in veteran population: Retrospective analysis of VACCR database. Cite
Subbiah S, Tashi T, Gonsalves W, Kalaiah M, Didwaniya N, Thota R, et al. Male breast cancer in veteran population: Retrospective analysis of VACCR database.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1031-1031 10.1200/jco.2010.28.15_suppl.1031
Individualized surveillance and follow-up based on breast cancer (BC) subtypes and risk of relapse in BC patients who received curative surgery. Cite
Lee S, Park Y, Sun J, Seo J, Lee J, Nam S, et al. Individualized surveillance and follow-up based on breast cancer (BC) subtypes and risk of relapse in BC patients who received curative surgery.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e11053-e11053 10.1200/jco.2010.28.15_suppl.e11053
Abstract 899: Patterns of distant and local relapses in breast cancer patients and triple negative subgroup Cite
Conson M, D'Amato G, Nieddu V, Pagliarulo C, Iorio V, Vernieri C, et al. Abstract 899: Patterns of distant and local relapses in breast cancer patients and triple negative subgroup. Epidemiology. American Association for Cancer Research; 2010; 10.1158/1538-7445.am10-899